Exelixis taps Genentech vet as EVP; Foundation Medicine inks fourth collaboration;

@FierceBiotech: Special Report: Top 15 blockbuster contenders in the biopharma pipeline. target="_blank"> | Follow @FierceBiotech

@JohnCFierce: Yesterday Lilly's CEO piously talked about measuring value by patient benefit. And how does Xigris do on that score? | Follow @JohnCFierce

@RyanMFierce: Guess which Big Pharma is developing 3 of Fierce's 15 top blockbuster contenders? | Follow @RyanMFierce

@MaureenFierce: Good to remember: If you want to start a company based on research done at your institution without a license, you can get thrown in jail. | Follow @MaureenFierce

> Exelixis ($EXEL) named J. Scott Garland as executive vice president and chief commercial officer. Garland is a Genentech vet, Genentech, where he served as vice president of its Avastin franchise. .fiercebiotech.com/press-releases/exelixis-appoints-executive-vice-president-and-chief-commercial-officer-0">Release

> Marlborough, MA-based Acton Pharmaceuticals has inked a licensing pact with Sanofi ($SNY) that will clear the way to bring a nasal spray for allergic rhinitis to the U.S. market. Report

> Just a couple of weeks after expanding its Series A round, Foundation Medicine announced its fourth collaboration with Johnson & Johnson Pharmaceutical Research and Development. Release

Pharma News

@FiercePharma: More in-demand jobs: med communications, which includes medical writing, editing, graphic design and science journalism. | Follow @FiercePharma

> Roche offers money-back deal on Avastin in Germany. News

> Novartis cost push claims 2,000 jobs in U.S., Switzerland. Report

> Amgen sets aside $780M for marketing settlement. Item

> Lilly pulls Xigris on failed septic-shock study. Article

> Collins: NIH targeting bottlenecks in drug development process. Report

Biotech Research News

> Biotech founder counters the skeptics with anti-aging program. Story

> Nanotech team at Stanford develops artificial super skin. More

> Antibody guards primates against lethal Hendra virus. Article

> Human studies of swine tissue transplants loom closer. Piece

> Small ALS stem cell study takes a big step forward. News

Manufacturing News

> 'Little things' blossomed into big QA trouble at J&J/McNeil. Article

> APP, Hospira resolve shortage of cytarabine. Item

> Actavis shipment of opioids stolen from truck stop. Report

> Astellas recall triggered by excess API in capsules. More

> Sanofi manufacturing glitch yields insulin pen shortage. Item

> Woodcock: More predictable manufacturing may ease regulations. Story

And Finally... The prestigious Rand Corp. says it will examine its review process after deciding to retract a bungled report on pot clinics and crime. Story

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.